SCHEMBL7804256

SCHEMBL7804256

CN1CCCC(C2c3ccccc3CCc3ccccc32)C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 7/20 0.57
CHRNA7 P36544 1/20 0.44
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
CYP2D6 P10635 1/20 0.43
TSHR P16473 1/20 0.43
CHRM2 P08172 1/20 0.43
HTR1A P08908 1/20 0.43
ADRA2A P08913 1/20 0.43
CHRM1 P11229 1/20 0.43
DRD1 P21728 1/20 0.43
TBXA2R P21731 1/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43
ADRA1A P35348 1/20 0.43
OPRM1 P35372 1/20 0.43
DRD3 P35462 1/20 0.43
KCNH2 Q12809 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
MAPT P10636 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8373553 0.82 SIGMAR1 (0.57) SIGMAR1CYP2D6MAPTKDM4EMEN1
SCHEMBL25501652 0.80 SIGMAR1 (0.42) SIGMAR1LMNATP53CYP2D6TSHR
SCHEMBL25501658 0.80 SIGMAR1 (0.42) SIGMAR1LMNATP53CYP2D6TSHR
SCHEMBL25501641 0.80 SIGMAR1 (0.42) SIGMAR1LMNATP53CYP2D6TSHR
SCHEMBL23848244 0.78 CHRNA7 (0.41) SIGMAR1CHRNA7OPRM1
SCHEMBL25171652 0.78 CA1 (0.42) CHRNA7TSHRALDH1A1
SCHEMBL23832762 0.78 CA1 (0.42) CHRNA7TSHRALDH1A1
SCHEMBL25502447 0.74 ALDH1A1 (0.41) CHRNA7CYP2D6TSHRALDH1A1CYP3A4
SCHEMBL9307181 0.73 SIGMAR1 (1.00) SIGMAR1
SCHEMBL861127 0.73 SIGMAR1 (0.63) SIGMAR1MAPTKDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230146127-A1 3-DIARYLMETHYLENES AND USES THEREOF ATUX ISKAY LLC 2023-05-11 US disclosed
EP-0733043-B1 TRICYCLIC DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING CORP (US) 2001-06-20 EP disclosed
US-5464840-A Pharmaceuticals to inhibit tumor necrosis factor-alpha and to treat septic shock, inflammation and allergic disease SCHERING CORPORATION (US) 1995-11-07 US disclosed
WO-1995015949-A1 TRICYCLIC DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING CORPORATION (US) 1995-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230146127-A1 3-DIARYLMETHYLENES AND USES THEREOF MYC, MYCBP, FOXO1 SIGMAR1 3676/4885CHRNA7 3918/4885LMNA 1859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.